• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , Aug. 24

Natco Pharma Ltd (NPL) has launched a drug for the treatment of multiple myeloma in the injection form under the brand Bortenat (Bortezomib) in 3.5 mg dosage. Multiple myeloma (characterised by the abnormal plasma cell in the bone marrow) is cancer of the plasma cell, which represents the immune system that produces immunoglobulins to help fight infection and disease, the company said in a press release here on Thursday. The company shas priced Bortenat at Rs 16,800 (MRP) as against Rs 75,000 for the imported medicine.

Being a pre-1995 invention, the company said it would not expect any litigation around this molecule. From among the several types of blood cancers, multiple myeloma is the second most prevalent and represents one per cent of all cancers.

More Stories on : New Products & Services | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Oriental Cuisine to expand operations

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line